Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Mediwound ( (MDWD) ) is now available.
On May 6, 2026, MediWound Ltd. held its 2026 annual general meeting of shareholders in Israel, where investors re-elected five incumbent directors to the board with overwhelming majorities, ensuring continuity in the company’s governance and strategic oversight. Shareholders also approved the reappointment of Somekh Chaikin, a KPMG member firm, as independent auditor for 2026 and endorsed an annual cash bonus for CEO Ofer Gonen for his 2025 performance, signaling strong support for current management and financial stewardship.
The meeting achieved quorum with 48.3% of outstanding ordinary shares present in person or by proxy as of the March 31, 2026 record date, reflecting solid but not full investor participation in corporate decision-making. The near-unanimous votes across all proposals under the Israeli Companies Law suggest broad shareholder alignment with the company’s leadership and compensation policies, which may bolster management’s mandate as MediWound advances its position in the competitive global wound-care and tissue-repair market.
The most recent analyst rating on (MDWD) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Mediwound stock, see the MDWD Stock Forecast page.
Spark’s Take on MDWD Stock
According to Spark, TipRanks’ AI Analyst, MDWD is a Neutral.
The score is held down primarily by weak financial performance (shrinking/volatile revenue, large losses, and sustained negative free cash flow) and a technically weak price trend (below key moving averages with negative MACD). The earnings call provides a partial offset via reaffirmed multiyear guidance, manufacturing expansion and trial progress, but execution, funding, and regulatory timing risks remain meaningful; valuation is also constrained by ongoing losses and no dividend yield data.
To see Spark’s full report on MDWD stock, click here.
More about Mediwound
MediWound Ltd. is an Israel-based biopharmaceutical company specializing in advanced therapies for tissue repair, with a focus on treating severe burns, chronic and hard-to-heal wounds, and related skin injuries. The company targets global hospital and specialty-care markets, leveraging proprietary enzymatic technologies to provide alternatives to surgical debridement and other invasive wound-care procedures.
Average Trading Volume: 83,357
Technical Sentiment Signal: Sell
Current Market Cap: $221.7M
For a thorough assessment of MDWD stock, go to TipRanks’ Stock Analysis page.